Nabriva Therapeutics plc
NBRVF
$0.0001
$0.000.00%
OTC PK
| 06/30/2023 | 03/31/2023 | 12/31/2022 | 09/30/2022 | 06/30/2022 | |
|---|---|---|---|---|---|
| Revenue | 2.24M | 7.59M | 10.57M | 9.15M | 9.19M |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 2.24M | 7.59M | 10.57M | 9.15M | 9.19M |
| Cost of Revenue | 10.16M | 5.76M | 23.29M | 8.45M | 8.54M |
| Gross Profit | -7.92M | 1.83M | -12.72M | 705.00K | 648.00K |
| SG&A Expenses | 4.11M | 4.90M | 9.61M | 11.91M | 11.05M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 14.27M | 10.67M | 32.90M | 20.36M | 19.59M |
| Operating Income | -12.02M | -3.08M | -22.33M | -11.20M | -10.40M |
| Income Before Tax | -12.06M | -8.70M | -22.47M | -10.99M | -10.69M |
| Income Tax Expenses | -- | -- | 309.00K | 520.00K | 385.00K |
| Earnings from Continuing Operations | -12.06M | -8.70M | -22.78M | -11.51M | -11.07M |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -12.06M | -8.70M | -22.78M | -11.51M | -11.07M |
| EBIT | -12.02M | -3.08M | -22.33M | -11.20M | -10.40M |
| EBITDA | -12.01M | -3.05M | -22.31M | -11.17M | -10.32M |
| EPS Basic | -3.73 | -2.72 | -7.32 | -4.21 | -4.38 |
| Normalized Basic EPS | -2.33 | -0.64 | -4.52 | -2.51 | -2.64 |
| EPS Diluted | -3.73 | -2.72 | -7.32 | -4.21 | -4.38 |
| Normalized Diluted EPS | -2.33 | -0.64 | -4.52 | -2.51 | -2.64 |
| Average Basic Shares Outstanding | 3.23M | 3.20M | 3.11M | 2.73M | 2.53M |
| Average Diluted Shares Outstanding | 3.23M | 3.20M | 3.11M | 2.73M | 2.53M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |